Ivan P. Gergel Sells 100,000 Shares of Nektar Therapeutics (NKTR) Stock
Nektar Therapeutics (NASDAQ:NKTR) SVP Ivan P. Gergel sold 100,000 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $24.14, for a total transaction of $2,414,000.00. Following the transaction, the senior vice president now owns 84,871 shares of the company’s stock, valued at approximately $2,048,785.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at 24.91 on Thursday. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.93. The stock has a 50 day moving average of $21.32 and a 200-day moving average of $20.37. The stock’s market capitalization is $3.89 billion.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.04). The firm had revenue of $34.60 million for the quarter, compared to the consensus estimate of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.36) earnings per share. Equities analysts forecast that Nektar Therapeutics will post ($0.98) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Ivan P. Gergel Sells 100,000 Shares of Nektar Therapeutics (NKTR) Stock” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/ivan-p-gergel-sells-100000-shares-of-nektar-therapeutics-nktr-stock/1609094.html.
A number of equities analysts have weighed in on NKTR shares. Jefferies Group LLC reiterated a “buy” rating and set a $23.00 target price on shares of Nektar Therapeutics in a research report on Friday, July 21st. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research report on Tuesday, August 1st. ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research report on Monday, June 26th. Finally, BidaskClub lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $26.80.
Several large investors have recently made changes to their positions in NKTR. BlackRock Inc. grew its stake in shares of Nektar Therapeutics by 180,432.9% during the 1st quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock valued at $470,234,000 after acquiring an additional 20,024,448 shares during the period. Janus Henderson Group PLC bought a new position in shares of Nektar Therapeutics during the 2nd quarter valued at approximately $34,661,000. PointState Capital LP grew its stake in shares of Nektar Therapeutics by 281.7% during the 2nd quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock valued at $33,841,000 after acquiring an additional 1,277,500 shares during the period. MARSHALL WACE ASIA Ltd bought a new position in shares of Nektar Therapeutics during the 1st quarter valued at approximately $23,580,000. Finally, Marshall Wace North America L.P. bought a new position in shares of Nektar Therapeutics during the 1st quarter valued at approximately $23,580,000. Institutional investors own 95.08% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.